Answers are grounded in this paper and cite their sources.
Recombinant interleukin-18 (IL-18) holds promise as a therapeutic for oncology, as a robust activator of adaptive and innate immune cells and a potent producer of IFN-γ. However, clinical success has been limited due to rapid upregulation of the natural IL-18 inhibitor, IL-18 binding protein (IL-18BP), and fast systemic clearance of active IL-18, unbound to IL-18BP. To overcome these limitations, human IL-18 and mouse orthologs were engineered with resistance to IL-18BP and extended half-life by fusion to an Fc scaffold, with the goal of creating an improved IL-18-based therapeutic. IL-18 variants with a range of potencies showed no detectable binding to IL-18BP and retained full biological activity in the presence of super-physiological levels of IL-18BP. Pharmacokinetic studies comparing the mouse orthologs with a “naked” IL-18BP resistant tool IL-18 variant confirmed the importance of half-life extension. Importantly, the mouse Fc orthologs exhibited stronger and more durable T H 1 cytokine production and expansion of cytotoxic NK cells and effector CD8 + T cells when compared to the naked IL-18 variant. Remarkably, mouse engineered IL-18 variants administered once a week demonstrated strong tumor growth inhibition and improved survival compared to vehicle treated mice in multiple syngeneic tumor models. Human IL-18 variants dosed in humanized mice mirrored in vivo findings from mouse orthologs, displaying extended pharmacokinetics and durable upregulation of serum T H 1 cytokines. These promising preclinical results highlight engineered IL-18 solutions that resist IL-18BP binding and extend half-life, unlocking its full potential for sustained anti-cancer immune responses. • Innovative IL-18 therapeutic engineered for cancer with IL-18BP resistance and Fc fusion. • IL-18 variants with a range of potencies retained activity in vitro despite IL-18BP. • Durable in vivo T H 1 immune responses induced by human and mouse IL-18 variants. • Demonstrated efficacy and improved survival in MC38, LLC1 and H22 mouse tumor models. • Advanced IL-18 protein engineering solutions designed to boost IL-18 therapeutic potential in cancer.
No takes yet. Share an insight, caveat, or question.
Dreaden et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: